Mov­ing up the lines, As­traZeneca stakes an­oth­er PhI­II win for Lyn­parza as ad­ju­vant breast can­cer ther­a­py

As­traZeneca and Mer­ck are now fair­ly cer­tain Lyn­parza works as an ad­ju­vant ther­a­py for BR­CA-mu­tat­ed high-risk HER2-neg­a­tive ear­ly breast can­cer.

That’s be­cause the in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee for its Phase III OlympiA tri­al con­clud­ed that the PARP in­hibitor crossed the su­pe­ri­or bound­ary ver­sus place­bo for in­va­sive dis­ease-free sur­vival — the main end­point — and rec­om­mend­ed that the com­pa­nies stop the tri­al ear­ly and move to pri­ma­ry analy­sis now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER